Newlin Investment Company

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors aimed at enhancing drug discovery and understanding cellular biology. The company creates Fluorogenic Activating Modules (FAMs) that enable precise detection of cellular trafficking, which is essential for high-throughput screening and subsequent analysis. Additionally, Sharp Edge Labs produces single-chain antibody fragments that activate specially designed fluorescent dyes and assays for receptor internalization. Their research focuses on addressing monogenic diseases, trafficking defects, and initiatives driven by patient needs. Key programs include efforts to correct the trafficking defect in deltaF508 CFTR to improve lung function, as well as developing trafficking assays for lysosomal storage disorders and Parkinson's disease. The company was initially known as Sharp Edge Technologies, Inc. and has been operational since its incorporation in 2010.

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, specializing in spatial intelligence software products for cancer diagnosis. Established in 2017, the company offers innovative solutions such as SpIntellx, which analyzes image data sets from various imaging platforms and reagent types, enabling precise analysis of pathology tissue sections. Additionally, SpIntellx provides HistoMapr, a computational guide for pathologists, and TumorMapr, which examines the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. By leveraging unbiased spatial analytics powered by explainable AI, SpIntellx aims to enhance the understanding of complex cancer biology, contributing to advancements in medicine and research across drug development, diagnostics, and treatment pipelines.

C2Sense, Inc. specializes in developing chemiresistive gas sensors and miniaturized sensing technologies aimed at enhancing food quality and safety, particularly in the food and agriculture sectors. Founded in 2013 and based in Cambridge, Massachusetts, the company’s sensors detect gases like ethylene and biogenic amines at low concentrations, allowing stakeholders throughout the supply chain—from growers to consumers—to monitor the freshness of fruits, meats, and other perishable goods, ultimately reducing waste. C2Sense is also advancing its Halo Diagnostics product, a digitally connected immunoassay reader that offers near-PCR sensitivity and facilitates real-time test results through a cloud-based, HIPAA-compliant platform. This technology supports remote healthcare by enabling physicians to access patient test results instantly. Additionally, C2Sense has developed versatile sensing solutions that provide product quality information and counterfeit detection, using safe molecular additives that report on the status of goods throughout the distribution process, thereby enhancing security in various sectors, including pharmaceuticals and luxury goods.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors aimed at enhancing drug discovery and understanding cellular biology. The company creates Fluorogenic Activating Modules (FAMs) that enable precise detection of cellular trafficking, which is essential for high-throughput screening and subsequent analysis. Additionally, Sharp Edge Labs produces single-chain antibody fragments that activate specially designed fluorescent dyes and assays for receptor internalization. Their research focuses on addressing monogenic diseases, trafficking defects, and initiatives driven by patient needs. Key programs include efforts to correct the trafficking defect in deltaF508 CFTR to improve lung function, as well as developing trafficking assays for lysosomal storage disorders and Parkinson's disease. The company was initially known as Sharp Edge Technologies, Inc. and has been operational since its incorporation in 2010.

Machine Translation answers the need of today’s global business for high volume and high velocity content localization and enterprise translation. Safaba provides Enterprise Machine Translation solutions to the world’s leading global enterprises.

Liquid X is a company specializing in the development of innovative metallic inks that enable the printing of functional components for various electronic devices. Their inks, which contain actual metal atoms rather than nanoparticles or metal flakes, offer superior properties such as high conductivity, thin and precise features, and excellent adhesion. This unique formulation allows for low-temperature processing and short production times, making it possible to use a wide range of substrates, including paper, gauze, and flexible plastics. Liquid X collaborates with manufacturers in the electronics industry to create applications such as sensors, heating elements, and smart textiles. The versatility of their inks supports various deposition methods, including inkjet, flexography, and gravure, positioning Liquid X as a key player in the emerging market for advanced electronic materials.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Plextronics specializes in the development of printed electronics, focusing on organic light-emitting diode (OLED) displays and lighting. The company creates conductive inks and associated process technologies that facilitate the mass production of printed devices, thereby reducing costs. Additionally, Plextronics is involved in the development of active layer technology for organic solar cells and plastic circuitry, further enhancing its portfolio in the realm of advanced electronic materials.